What are the best treatments for HFE hereditary haemochromatosis?

The primary treatment for HFE hereditary haemochromatosis is therapeutic phlebotomy, which involves the regular removal of blood to reduce iron stores to safe levels. For patients who cannot tolerate phlebotomy or have specific complications, iron chelation therapy may be used, though it is considered a secondary intervention in the management of HFE hereditary haemochromatosis.

What is the standard of care for HFE hereditary haemochromatosis?

The gold standard for treating HFE hereditary haemochromatosis is therapeutic phlebotomy (bloodletting). The goal is to reach and maintain serum ferritin levels typically between 50 and 100 ng/mL. In the initial "induction" phase, blood is removed weekly or bi-weekly until iron overload is corrected. Once iron levels are stabilized, patients move to a "maintenance" phase, where phlebotomy is performed only as needed to keep iron levels within a target range.

Are medications used to treat this condition?

Pharmacological intervention is generally reserved for patients who cannot undergo phlebotomy or have specific contraindications. Common iron chelators used in clinical practice include:

• Deferoxamine (Desferal): Administered via subcutaneous infusion.


• Deferasirox (Exjade, Jadenu): An oral medication used when phlebotomy is ineffective or poorly tolerated.


• Deferiprone (Ferriprox): Another oral option occasionally utilized in specific clinical scenarios.

Which specialists should be on the care team?

Managing HFE hereditary haemochromatosis requires a multidisciplinary approach to monitor organ health and prevent long-term damage. Your care team should ideally include:

• Hematologist: To oversee phlebotomy schedules and iron studies.


• Hepatologist: To monitor liver health, especially if cirrhosis or fibrosis is present.


• Gastroenterologist: To manage digestive symptoms or complications.


• Cardiologist: If the heart has been affected by iron deposition (cardiomyopathy).


• Endocrinologist: To monitor for secondary conditions like diabetes or hypogonadism.

How does treatment effectiveness vary?

Treatment success in HFE hereditary haemochromatosis depends heavily on the stage of the disease at diagnosis. Patients diagnosed before the development of organ damage (such as cirrhosis or heart failure) often have a normal life expectancy. Conversely, those with established organ damage may require ongoing support for those specific complications even after iron levels are normalized. Our community of 828 members at DiseaseMaps.org highlights that individual responses to phlebotomy frequency can vary significantly based on diet, lifestyle, and genetic penetrance.

Next steps

• Consult a hematologist to establish an individualized phlebotomy schedule.


• Monitor serum ferritin and transferrin saturation levels regularly as directed by your physician.


• Connect with the 828 members of our HFE hereditary haemochromatosis community on DiseaseMaps.org to share experiences.


• Discuss with your doctor whether genetic counseling is appropriate for your family members.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; always consult your healthcare provider for personalized treatment decisions.

References

• NIH Genetic and Rare Diseases Information Center (GARD): HFE-related hemochromatosis.


• Orphanet: HFE-related haemochromatosis.


• OMIM (Online Mendelian Inheritance in Man): Hemochromatosis, Type 1.


• Iron Disorders Institute: Guidelines for the management of iron overload.